Related Experiment Videos
Expression of the ras oncogene in gynecologic tumors
T J O'Brien1, G A Bannon, D S Bard
1Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock 72205.
Abstract:
Control of oncogene expression has been shown to be a coordinated regulatory mechanism in normal growth and development. Overt expression of these genes also has been noted in transformed or neoplastic cell types. The ras family of oncogenes has been shown to be particularly evident among genes expressed in malignant tissues. We provide evidence, using ribonucleic acid dot analysis and Western blot analysis of gynecologic tumor extracts, that ras expression may be a common occurrence in these malignancies. Furthermore, the ras-related peptides can be detected in sera of some patients with tumors.
Insights
Ras oncogene expression is common in gynecologic cancers, with related peptides detectable in some patient sera. This suggests ras oncogenes play a role in these malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogene expression is crucial for cellular growth and development.
- Aberrant oncogene expression, particularly ras, is linked to neoplastic and malignant cell types.
- Ras oncogenes are frequently observed in various malignant tissues.
Purpose of the Study:
- To investigate the prevalence of ras oncogene expression in gynecologic tumors.
- To determine if ras-related peptides are detectable in the sera of patients with these tumors.
Main Methods:
- Ribonucleic acid (RNA) dot analysis was employed to assess gene expression.
- Western blot analysis was used to detect ras-related peptides in tumor extracts.
- Serum samples from patients were analyzed for the presence of ras-related peptides.
Main Results:
- Evidence indicates that ras expression is a common occurrence in gynecologic malignancies.
- Ras-related peptides were detected in the sera of some patients diagnosed with these tumors.
Conclusions:
- Ras oncogene expression appears to be a frequent event in gynecologic cancers.
- The detection of ras-related peptides in patient sera suggests a potential biomarker role for ras in these malignancies.